Tanezumab: a selective humanized mAb for chronic lower back pain

Figures & data

Table 1 Comparison of average lower back pain intensity scores

Pain intensity scores	Tanezumab 20 mg	Tanezumab 10 mg	Tanezumab 5 mg	Naproxen 500 mg BID	Placebo
Baseline mean (SD)	6.74 (1.48)	6.57 (1.39)	6.62 (1.36)	6.77 (1.38)	6.71 (1.37)
LS mean change (SE)	−2.18 (0.14)	−2.06 (0.14)	−1.58 (0.16)	−1.66 (0.114)	−1.25 (0.16)
P-value vs placebo	<0.001	<0.001	0.113	0.037
P-value vs naproxen	0.006	0.035	0.688

Notes: Low back intensity scores are rated on a scale of 0–10. Data from Kivitz et al.¹⁹

Table 2 Comparison of Roland Morris Disability Questionnaire scores

Pain intensity scores	Tanezumab 20 mg	Tanezumab 10 mg	Tanezumab 5 mg	Naproxen 500 mg BID	Placebo
Baseline mean (SD)	13.00 (4.97)	12.98 (5.11)	12.24 (4.92)	12.86 (4.93)	12.79 (4.74)
LS mean change (SE)	−2.80 (0.26)	−3.18 (0.26)	−2.37 (0.29)	−2.07 (0.26)	−1.75 (0.29)
P-value vs placebo	0.006	<0.001	0.125	0.405
P-value vs naproxen	0.042	0.002	0.428

Notes: Roland Morris Disability Questionnaire scores range from 0 to 2 with lower scores associated with better function. Data from Kivitz et al.¹⁹

KivitzAJGimbelJSBramsonCEfficacy and safety of tanezumab versus naproxen in the treatment of chronic low back painPain201315471009102123628600

 PubMed Web of Science ®Google Scholar